Volume | 43 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Mind Medicine MindMed Inc | MNMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
9.50 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
4 | 43 | - | 2.41 - 11.10 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
04:25:49 | 1 | US$ 9.50 | USD |
Mind Medicine MindMed (MNMD) Options Flow Summary
Mind Medicine MindMed Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.89M | 41.33M | - | 0 | -95.73M | -2.32 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Mind Medicine MindMed News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MNMD Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.02 | 10.84 | 9.33 | 9.90 | 2,733,692 | -0.52 | -5.19% |
1 Month | 5.49 | 11.10 | 5.47 | 9.01 | 4,489,956 | 4.01 | 73.04% |
3 Months | 3.60 | 11.10 | 3.49 | 7.96 | 2,015,879 | 5.90 | 163.89% |
6 Months | 3.52 | 11.10 | 2.41 | 6.89 | 1,206,494 | 5.98 | 169.89% |
1 Year | 2.91 | 11.10 | 2.41 | 6.02 | 853,981 | 6.59 | 226.46% |
3 Years | 85.3005 | 86.55 | 2.12 | 28.07 | 3,308,414 | -75.80 | -88.86% |
5 Years | 85.3005 | 86.55 | 2.12 | 28.07 | 3,308,414 | -75.80 | -88.86% |
Mind Medicine MindMed Description
Mind Medicine Inc is a psychedelic medicine biotech company that discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The firm is having an approach towards developing the next generation of psychedelic inspired medicines and therapies. |